Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alfasigma SpA

http://www.alfasigma.com

Latest From Alfasigma SpA

Gilead Offers Up $4.3bn For CymaBay And Phase III PBC Candidate

Adding to its liver disease portfolio, Gilead agreed to pay a 27% premium for CymaBay and seladelpar, which has a 14 August FDA action date to compete in second-line primary biliary cholangitis.

M & A Business Strategies

Ipsen In Pole Position For Rare Liver Disease

The FDA is set to make a decision on elafibranor for primary biliary cholangitis by June next year, which could give Ipsen a head start over CymaBay's seladelpar.

Business Strategies Deals

CymaBay Appears Stronger Threat To Ocaliva In PBC Than Ipsen/Genfit

CymaBay and Genfit have been positioning their failed NASH candidates, both PPAR agonists, for approval in second-line primary biliary cholangitis. Analysts call both approvable, but say CymaBay’s drug has a better overall profile.

Business Strategies Clinical Trials

Durect Eyes Phase III In Alcoholic Hepatitis Despite Phase IIb Miss

Durect thinks its epigenetic modulator shows promise with data showing reduction in 90-day mortality despite missing the primary endpoint of mortality and liver transplant rate.

Clinical Trials Business Strategies
See All

Company Information

UsernamePublicRestriction

Register